SUPN
Supernus Pharmaceuticals Inc
43.30$
-0.2%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 12.7% | 11.9% | 11.4% | 10.6% | 10.0% | 15.0% | 10.5% | 10.2% | 9.9% | 10.9% | 11.3% | 15.4% | 11.9% | |
| 87.3% | 88.1% | 88.6% | 89.4% | 90.0% | 85.0% | 89.5% | 89.8% | 90.1% | 89.1% | 88.7% | 84.6% | 88.1% | |
| 14.7% | 14.2% | 17.4% | 15.6% | 16.5% | 16.4% | 18.0% | 13.4% | 15.3% | 13.2% | 19.0% | 13.4% | 15.2% | |
| 16.8% | 15.8% | 18.8% | 16.1% | 8.8% | 14.2% | 17.8% | 17.2% | 53.4% | 18.5% | 60.3% | 18.6% | 37.1% | |
| 82.0% | 88.7% | 90.8% | 75.9% | 66.7% | 72.7% | 96.3% | 82.5% | 121.5% | 82.6% | 92.7% | 111.1% | 101.6% | |
| 5.3% | -0.6% | -2.2% | 13.4% | 23.2% | 12.3% | -6.8% | 7.3% | -31.4% | 6.5% | -3.6% | -26.5% | -13.5% | |
| 0.0% | 2.9% | 0.0% | 0.0% | 0.0% | 0.0% | – | 0.0% | – | – | – | 1.1% | – | |
| 6.4% | 0.6% | 0.2% | 15.6% | 25.6% | 15.1% | -3.9% | 10.1% | -30.2% | -0.9% | -2.9% | -26.3% | -14.9% | |
| 16.8% | -0.1% | 0.1% | 3.8% | 3.7% | 6.3% | 4.0% | -3.5% | -6.7% | 1.0% | -1.8% | 0.3% | -1.6% | |
| -10.4% | 0.7% | 0.1% | 11.8% | 21.9% | 8.8% | -7.9% | 13.6% | -23.5% | -1.9% | -1.1% | -26.6% | -13.2% | |
| 20.6% | 13.8% | 11.5% | 23.1% | 37.0% | 26.0% | 11.9% | 23.0% | -17.3% | 12.6% | 9.7% | -13.5% | -1.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.